Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD

✍ Scribed by Yeni Kim; Min-Sup Shin; Jae-Won Kim; Hee-Jung Yoo; Soo-Churl Cho; Boong-Nyun Kim

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 129 KB
• Volume: 24
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.1010

✦ Synopsis

Abstract

Objectives

This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH‐IR) to osmotic release oral system methylphenidate (OROS‐MPH).

Methods

102 children with attention‐deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH‐IR to OROS‐MPH.

Results

There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH‐IR to OROS‐MPH. A positive correlation was observed between the improvement in parent/caregiver‐rated IOWA Conners total score (Δ IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver‐rated IOWA Conners scale total scores were significant predictors of change in commission error (β = 0.3, p = 0.005, CI = 0.4–2.3, adjusted R^2^ = 0.12) and RT variability (β = 0.3, p = 0.004, CI = 0.5–2.4, adjusted R^2^ = 0.09) of visual CPT.

Conclusions

These data suggest that MPH‐IR may be successfully switched to OROS‐MPH treatment with associated improvements in neurocognitive performance. Large‐scale controlled trials are needed to replicate these findings. Copyright © 2009 John Wiley & Sons, Ltd.